HIV/AIDS Clinical Trials in Philadelphia

Showing 161-180 of 315 trials

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178

This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded study to evaluate the safety, tolerability, and acceptability of GSK1265744 long acting injectable formulation (744 LA) in adult male subjects. To evaluate the safety and tolerability of the injectable agent, 744 LA (800 milligrams (mg) dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men. Eligible participants will be randomized in a 5:1 ratio to receive 744 LA or matching placebo. Participants will receive daily oral 744 (30 mg tablets) or matching placebo for 4 weeks during the Oral Phase of the study, followed by a one week washout period. Following safety lab assessments from the Oral Phase, participants will enter the Injection Phase and receive Intramuscular (IM) injections of 744 LA or placebo at three time points at 12 week intervals. IM injections will consist of 800 mg of 744 or a matching control

Infection, Human Immunodeficiency Virus

ViiV Healthcare127 participantsStarted Mar 2014

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +7 more locations

TERMINATEDPHASE2< 1 mile

Telephone Support to Improve Adherence to Anti-HIV Medications

NCT00988442

This study tested a system of nursing telephone support to determine if it improves adherence to antiretroviral therapy (ART) in at-risk, treatment-experienced people.

HIV Infections

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections59 participantsStarted Oct 2010

Birmingham, Alabama, United States • San Diego, California, United States • Chicago, Illinois, United States +13 more locations

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Telephone Support to Improve Adherence to Anti-HIV Medications

HIV/AIDS Trials in Other Cities

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

GW873140 In Combination With Combivir In HIV Infected Subjects

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

PRO 140 for Human Immunodeficiency Virus Infection

Integrated Treatment of Marijuana Abuse for HIV+ Youth

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

Linkage to Care - Part II

CDC-ATN Linkage Evaluation

Factors Affecting PrEP Adherence

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Feasibility of Using a Structured Daily Diary

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Engaging Care for HIV-infected Adolescent Females.

Intervention for Newly Diagnosed Youth With HIV

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

Other Conditions in Philadelphia